EA200000331A1 - Фармацевтические композиции, содержащие белок плазмы - Google Patents

Фармацевтические композиции, содержащие белок плазмы

Info

Publication number
EA200000331A1
EA200000331A1 EA200000331A EA200000331A EA200000331A1 EA 200000331 A1 EA200000331 A1 EA 200000331A1 EA 200000331 A EA200000331 A EA 200000331A EA 200000331 A EA200000331 A EA 200000331A EA 200000331 A1 EA200000331 A1 EA 200000331A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
plasma protein
compositions containing
active compound
water
Prior art date
Application number
EA200000331A
Other languages
English (en)
Other versions
EA004700B1 (ru
Inventor
Лайош Хегедюш
Кристина Кремпельш
Кристина Пааль
Габор Петё
Original Assignee
Хьюман Рт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хьюман Рт filed Critical Хьюман Рт
Publication of EA200000331A1 publication Critical patent/EA200000331A1/ru
Publication of EA004700B1 publication Critical patent/EA004700B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение касается водорастворимых препаратов и фармацевтических композиций в твердой или жидкой форме, в основном для парентерального применения. Они состоят или в их состав входят терапевтически активное соединение (имеющее низкую растворимость в воде и существенное сродство связывания с белками плазмы) и белковая фракция плазмы в контролируемом агрегационном состоянии, вследствие чего указанное активное соединение и указанная белковая фракция связаны друг с другом нековалентными связями. Оно также охватывает способы получения препарата и фармацевтической композиции.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000331A 1997-09-18 1998-09-17 Фармацевтические композиции, содержащие белок плазмы EA004700B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins
PCT/HU1998/000086 WO1999013914A1 (en) 1997-09-18 1998-09-17 Pharmaceutical compositions containing plasma protein

Publications (2)

Publication Number Publication Date
EA200000331A1 true EA200000331A1 (ru) 2000-10-30
EA004700B1 EA004700B1 (ru) 2004-06-24

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000331A EA004700B1 (ru) 1997-09-18 1998-09-17 Фармацевтические композиции, содержащие белок плазмы

Country Status (33)

Country Link
US (5) US6743826B1 (ru)
EP (1) EP0981375B1 (ru)
JP (1) JP2001508806A (ru)
KR (1) KR100587962B1 (ru)
CN (1) CN1189216C (ru)
AR (1) AR017120A1 (ru)
AT (1) ATE230611T1 (ru)
AU (1) AU734695B2 (ru)
BG (1) BG64749B1 (ru)
BR (1) BR9812469A (ru)
CA (1) CA2269923C (ru)
CZ (1) CZ301326B6 (ru)
DE (1) DE69810612T2 (ru)
DK (1) DK0981375T3 (ru)
EA (1) EA004700B1 (ru)
ES (1) ES2187062T3 (ru)
HR (1) HRP980499A2 (ru)
HU (1) HUP9701554D0 (ru)
IL (1) IL135055A (ru)
LT (1) LT4736B (ru)
LV (1) LV12493B (ru)
NO (1) NO325294B1 (ru)
NZ (1) NZ503302A (ru)
PL (1) PL193067B1 (ru)
PT (1) PT981375E (ru)
RO (1) RO118695B1 (ru)
RS (1) RS50102B (ru)
SI (1) SI20189B (ru)
SK (1) SK284683B6 (ru)
TR (1) TR200001545T2 (ru)
TW (1) TWI222365B (ru)
WO (1) WO1999013914A1 (ru)
ZA (1) ZA988585B (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
DE60023324T2 (de) 1999-09-16 2006-07-20 Novo Nordisk A/S Zusammensetzung zur in-vitro befruchtung
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
AU2001253334A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
MXPA05000615A (es) 2002-07-16 2005-11-17 Medexis S A Conjugados esteroideos, preparacion de los mismos y usos de los mismos.
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
WO2006035443A2 (en) * 2004-09-29 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Monitoring of convection enhanced drug delivery
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
RU2283133C1 (ru) * 2005-06-03 2006-09-10 Общество С Ограниченной Ответственностью "Ферон" Лечебное средство
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
JPWO2009116557A1 (ja) * 2008-03-21 2011-07-21 富士フイルム株式会社 薬剤含有組成物
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
BR112012002963A2 (pt) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038068A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
CA2784826A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
EP2531173B1 (en) * 2010-02-03 2018-09-26 Oncbiomune, L.L.C. Taxane- and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AU2015232994B2 (en) 2014-03-18 2020-05-28 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
EP3978618A1 (en) * 2015-05-08 2022-04-06 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US10500285B2 (en) 2015-05-15 2019-12-10 Zhuhai Beihai Biotech Co., Ltd. Docetaxel and human serum albumin complexes
WO2016205654A1 (en) * 2015-06-18 2016-12-22 Aquarius Biotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
SG11201805942UA (en) 2016-01-11 2018-08-30 Epicentrx Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EP4019023A1 (en) * 2016-08-03 2022-06-29 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CN115487312B (zh) 2016-10-27 2025-02-07 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
AU2018231789B2 (en) 2017-03-09 2024-02-22 Izun Pharmaceuticals Corp. Stabilized protein-bound cannabinoid compositions
EP3602065A4 (en) 2017-03-20 2020-12-23 Spectral Platforms, Inc. SPECTROSCOPY METHODS TO DETECT AND CHARACTERIZE MICRO-ORGANISMS
KR102869384B1 (ko) 2017-07-07 2025-10-15 에피센트알엑스, 인코포레이티드 치료제의 비경구 투여를 위한 조성물
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
WO2019170848A1 (en) * 2018-03-09 2019-09-12 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
US20230190699A1 (en) 2020-02-04 2023-06-22 Zhuhai Beihai Biotech Co., Ltd. Formulations of docetaxel
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料
US20240199721A1 (en) * 2021-06-29 2024-06-20 Genecell Biotech Inc. Plant cell line for producing albumin at high efficiency and use thereof
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法
CN116212639A (zh) * 2023-02-28 2023-06-06 湖南科伦制药有限公司 一种去除药液中有机溶剂的方法及系统
CN116297963B (zh) * 2023-03-24 2024-12-27 四川汇宇制药股份有限公司 一种白蛋白结合型紫杉醇注射剂中辛酸钠含量的检测方法
CN120789284A (zh) * 2025-09-18 2025-10-17 通化安睿特生物制药股份有限公司 一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (ru) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
US8946167B2 (en) 2015-02-03
ZA988585B (en) 2000-03-13
PL193067B1 (pl) 2007-01-31
NO20001371L (no) 2000-05-18
EP0981375A1 (en) 2000-03-01
LV12493A (en) 2000-06-20
US6743826B1 (en) 2004-06-01
HUP9701554D0 (en) 1997-11-28
EP0981375B1 (en) 2003-01-08
PL339369A1 (en) 2000-12-18
US20070232536A1 (en) 2007-10-04
TWI222365B (en) 2004-10-21
IL135055A (en) 2004-09-27
AU734695B2 (en) 2001-06-21
KR20010052072A (ko) 2001-06-25
US7501455B2 (en) 2009-03-10
CN1270529A (zh) 2000-10-18
KR100587962B1 (ko) 2006-06-13
IL135055A0 (en) 2001-05-20
US7119124B2 (en) 2006-10-10
CA2269923C (en) 2003-07-22
DE69810612D1 (de) 2003-02-13
DE69810612T2 (de) 2003-10-02
AR017120A1 (es) 2001-08-22
US20050064028A1 (en) 2005-03-24
BG104245A (en) 2000-11-30
SI20189A (sl) 2000-10-31
NZ503302A (en) 2001-08-31
CZ2000952A3 (cs) 2000-09-13
EA004700B1 (ru) 2004-06-24
SK3292000A3 (en) 2000-08-14
CA2269923A1 (en) 1999-03-25
AU9362398A (en) 1999-04-05
NO325294B1 (no) 2008-03-17
LV12493B (en) 2001-01-20
BG64749B1 (bg) 2006-02-28
HRP980499A2 (en) 1999-12-31
PT981375E (pt) 2003-04-30
JP2001508806A (ja) 2001-07-03
ATE230611T1 (de) 2003-01-15
BR9812469A (pt) 2002-02-05
ES2187062T3 (es) 2003-05-16
SK284683B6 (sk) 2005-09-08
LT4736B (lt) 2000-12-27
US20100076008A1 (en) 2010-03-25
YU16600A (sh) 2003-08-29
TR200001545T2 (tr) 2000-10-23
CN1189216C (zh) 2005-02-16
NO20001371D0 (no) 2000-03-16
US20040014655A1 (en) 2004-01-22
WO1999013914A1 (en) 1999-03-25
DK0981375T3 (da) 2003-05-05
RS50102B (sr) 2009-01-22
LT2000018A (en) 2000-08-25
RO118695B1 (ro) 2003-09-30
SI20189B (sl) 2007-10-31
CZ301326B6 (cs) 2010-01-20

Similar Documents

Publication Publication Date Title
BR9812469A (pt) Composições farmacêuticas contendo proteina de plasma
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
EA200500644A1 (ru) Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
EA200300942A1 (ru) Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
EA199900979A1 (ru) Композиции активированного протеина
BRPI0516284A (pt) anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
WO2002044215A3 (en) Hybrid antibodies
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
BRPI0406801B8 (pt) derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
RU93004445A (ru) Новые 2-циано 3-гидроксиенамидные производные, способ их получения, их применение в качестве медикаментов, содержащие их фармацевтические композиции и новые полученные промежуточные продукты
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
EA200501129A1 (ru) Парентеральные композиции пептида для лечения системной красной волчанки
AU7525398A (en) Inhibitors for urokinase receptor
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
WO2005056794A3 (en) Agents for the regulation of transcription via zinc-finger proteins
BR0215037A (pt) Composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
FA9A Withdrawal of a eurasian application
NF9A Restoration of lapsed right to a eurasian application

Designated state(s): AM AZ KG MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ

MK4A Patent expired

Designated state(s): AM BY RU